Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDE574 |
| Synonyms | |
| Therapy Description |
IDE574 is a selective lysine acetyltransferase (KAT) inhibitor that targets KAT6 and KAT7, which may lead to antitumor activity (Cancer Res (2026) 86 (7_Supplement): 4483). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDE574 | IDE 574|IDE-574 | IDE574 is a selective lysine acetyltransferase (KAT) inhibitor that targets KAT6 and KAT7, which may lead to antitumor activity (Cancer Res (2026) 86 (7_Supplement): 4483). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07540572 | Phase Ib/II | Fulvestrant + IDE574 IDE574 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | Recruiting | USA | 0 |